Jiang Kui-Ying, Qi Li-Li, Liu Xin-Bo, Wang Yong, Wang Ling
Department of Orthopedic Oncology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Experimental Teaching Center, Hebei Medical University, Shijiazhuang, Hebei, China.
Front Oncol. 2023 Jan 11;12:1073932. doi: 10.3389/fonc.2022.1073932. eCollection 2022.
Siglec-15 is expressed in a variety of cancers. However, the role of Siglec-15 in the prognosis of cancer patients remains controversial. Therefore, we conducted a meta-analysis to clarify the potential prognostic value of Siglec-15 in solid tumors.
The PubMed, Web of Science, Embase and CNKI databases were comprehensively searched to identify studies assessing the effect of Siglec-15 on the survival of cancer patients. Hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS), progression-free survival (PFS) and disease-specific survival (DSS) from individual studies were evaluated.
The data from 13 observational studies consisting of 1376 patients were summarized. Elevated baseline Siglec-15 expression was significantly correlated with poor OS (pooled HR = 1.28, 95% CI: 1.05-1.56; P = 0.013). However, high Siglec-15 expression predicted a significantly better DSS (pooled HR = 0.73 (95% CI: 0.57-0.94; P = 0.015) but not PFS (pooled HR = 1.49, 95% CI: 0.46-4.87; P=0.510). In addition, high Siglec-15 expression was not associated with PD-L1 (OR=0.64, 95% CI: 0.42-0.95; P = 0.028). High Siglec-15 expression was associated with male sex (OR = 1.39, 95% CI: 1.05-1.84; P = 0.022), larger tumor size (OR = 1.896, 95% CI: 1.26-2.9; P = 0.002), and advanced tumor-node-metastasis (TNM) stage (OR = 1.84; 95% CI: 1.19-2.84; P =0.006) in solid tumors.
This updated study suggested the expression of Siglec-15 is significantly associated with poor outcomes in human solid tumors, but further studies are needed to determine the prognostic value of Siglec-15 in solid tumors.
Siglec-15在多种癌症中均有表达。然而，Siglec-15在癌症患者预后中的作用仍存在争议。因此，我们进行了一项荟萃分析，以阐明Siglec-15在实体瘤中的潜在预后价值。
全面检索PubMed、Web of Science、Embase和中国知网数据库，以确定评估Siglec-15对癌症患者生存影响的研究。对各研究中总生存期（OS）、无进展生存期（PFS）和疾病特异性生存期（DSS）的风险比（HR）及95%置信区间（CI）进行评估。
总结了来自13项观察性研究、共1376例患者的数据。基线Siglec-15表达升高与较差的OS显著相关（合并HR = 1.28，95% CI：1.05 - 1.56；P = 0.013）。然而，高Siglec-15表达预测DSS显著更好（合并HR = 0.73（95% CI：0.57 - 0.94；P = 0.015），但与PFS无关（合并HR = 1.49，95% CI：0.46 - 4.87；P = 0.510）。此外，高Siglec-15表达与PD-L1无关（OR = 0.64，95% CI：0.42 - 0.95；P = 0.028）。在实体瘤中，高Siglec-15表达与男性（OR = 1.39，95% CI：1.05 - 1.84；P = 0.022）、更大的肿瘤大小（OR = 1.896，95% CI：1.26 - 2.9；P = 0.002）和晚期肿瘤-淋巴结-转移（TNM）分期（OR = 1.84；95% CI：1.19 - 2.84；P = 0.006）相关。
这项更新的研究表明，Siglec-15的表达与人类实体瘤的不良预后显著相关，但需要进一步研究来确定Siglec-15在实体瘤中的预后价值。
